Compile Data Set for Download or QSAR
maximum 50k data
Found 5344 with Last Name = 'kotian' and Initial = 'pl'
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50579244(Avoralstat | BCX-4161)
Affinity DataKi:  0.260nMAssay Description:Inhibition of purified human plasma kallikrein assessed as inhibition constant using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by m...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416926((+)-1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl...)
Affinity DataKi:  0.440nMAssay Description:Inhibition of purified human plasma kallikrein assessed as inhibition constant using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by m...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416770(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416773(1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416774(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416775(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416777(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416779(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416780(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416782(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416783(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416784(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416785(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416786(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416787(1-(3-(aminomethyl)phenyl)-N-(3-cyclopropyl-5-((cyc...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416788(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416789(1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416790(1-(3-(Aminomethyl)phenyl)-N-(2-chloro-5-((cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416791(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416792(1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416794(Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416795(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416796(1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416797(1-(3-(aminomethyl)phenyl)-N-(5-fluoro-2-methyl-1,2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416798(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416799(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416988((+)-N-(3-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416989((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416991((+)-N-(3-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416992((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416993((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM439578(US10633345, Compound 257b | US10689346, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416996((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416998((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416993((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417000((+-)-1-(3-(aminomethyl)phenyl)-3-cyano-N-(5-((cycl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417001((+)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417003((+)-1-(3-carbamimidoylphenyl)-N-(5-((3-cyanophenyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417006((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417007((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417008((+)-N-(5-(1-amino-1-(6-cyanopyridin-2-yl)-3-cyclop...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417009(1-(3-carbamimidoylphenyl)-N-(5-((+-)-3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417012((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417013(1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417014((+-)-N-(5-(1-amino-1-(3-carbamoylphenyl)-3-cyclopr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416939(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM417018((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 5344 total ) | Next | Last >>
Jump to: